Skip to content
HowShorted

Esperion Therapeutics, Inc. short interest in 2018

In 2018, Esperion Therapeutics, Inc.'s disclosed short interest ran from 10.29% of shares outstanding on 12 Jan 2018 to 16.63% on 31 Dec 2018, a change of +6.34 percentage points. The year's high was 27.11% on 15 Jun 2018 and its low 10.02% on 15 Feb 2018, averaging 18.96% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.47 days on 14 Sep 2018. Full history: Esperion Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Esperion Therapeutics, Inc. in 2018

2018 in figures

Start of year
10.29% (12 Jan 2018)
End of year
16.63% (31 Dec 2018)
Change
+6.34 pp
High
27.11% (15 Jun 2018)
Low
10.02% (15 Feb 2018)
Average
18.96%
Highest days to cover
14.47 (14 Sep 2018)
SEC filings marked
8

Every report in 2018

Esperion Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201810.29%5.45
31 Jan 201812.67%5.33
15 Feb 201810.02%4.16
28 Feb 201810.16%4.7610-K filed, results (8-K)
15 Mar 201810.89%3.36
29 Mar 201813.05%5.29
13 Apr 201813.07%6.37
30 Apr 201814.88%9.88
15 May 201819.26%1.2610-Q filed, results (8-K)
31 May 201826.30%6.33
15 Jun 201827.11%7.93
29 Jun 201825.39%9.74
13 Jul 201824.88%6.78
31 Jul 201826.67%13.28
15 Aug 201822.99%11.4010-Q filed, results (8-K)
31 Aug 201822.80%9.29
14 Sep 201823.29%14.47
28 Sep 201821.35%9.80
15 Oct 201819.05%10.24
31 Oct 201821.26%5.40
15 Nov 201823.71%6.2710-Q filed, results (8-K)
30 Nov 201818.93%8.39
14 Dec 201820.46%10.51
31 Dec 201816.63%6.84

See also: Esperion Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.